Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score

Journal of Clinical Oncology

Volumn 24, Issue 16, 2006, Pages 2472-2479

  Went, Philip ^b   Agostinelli, Claudio ^b   Gallamini, Andrea ^b   Piccaluga, Pier Paolo ^b   Ascani, Stefano ^b   Sabattini, Elena ^b   Bacci, Francesco ^b   Falini, Brunangelo ^b   Motta, Teresio ^b   Paulli, Marco ^b   Artusi, Tullio ^b   Piccioli, Milena ^b   Zinzani, Pier Luigi ^b   Pileri, Stefano A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD15 ANTIGEN; CD30 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; LACTATE DEHYDROGENASE; SMALL INTERFERING RNA; CD2 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; KI 67 ANTIGEN; LEUKOCYTE ANTIGEN; MEMBRANE METALLOENDOPEPTIDASE; TUMOR MARKER;

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY; ADULT; AGED; CHEMISTRY; CLINICAL TRIAL; FOLLOW UP; GENE EXPRESSION REGULATION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD15; ANTIGENS, CD2; ANTIGENS, CD20; ANTIGENS, CD3; ANTIGENS, CD30; ANTIGENS, CD4; ANTIGENS, CD5; ANTIGENS, CD7; ANTIGENS, CD8; CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MULTICENTER STUDIES; NEPRILYSIN; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33744992010     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.6327     Document Type: Article

References (72)

1. Jaffe ES, Harris NL, Stein H, et al: Pathology and genetics: Tumours of haematopoietic and lymphoid tissues, in Kleihues P, Sobin LH (eds): WHO Classification of Tumours. Lyon, France, IARC Press, 2001, pp 227-229
2. Escalon MP, Liu NS, Yang Y, et al: Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: The M.D. Anderson Cancer Center experience. Cancer 103:2091-2098, 2005
3. Zucca E, Zinzani PL: Understanding the group of peripheral T-cell lymphomas, unspecified. Curr Hematol Rep 4:23-30, 2005
4. Evens AM, Gartenhaus RB: Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 5:289-303, 2004
5. Lopez-Guillermo A, Cid J, Salar A, et al: Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 9:849-855, 1998
6. Gisselbrecht C, Gaulard P, Lepage E, et al: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas: Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92:76-82, 1998
7. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients: The Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 8:973-978, 1997
8. Jantunen E, Wiklund T, Juvonen E, et al: Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: A nation-wide survey. Bone Marrow Transplant 33:405-410, 2004
9. Kahl C, Leithauser M, Wolff D, et al: Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol 81:646-650, 2002
10. Kojima H, Hasegawa Y, Suzukawa K, et al: Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification. Leuk Res 28:1287-1292, 2004
11. Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004
12. Ansell SM, Habermann TM, Kurtin PJ, et al: Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 15:2296-2301, 1997
13. Rudiger T, Weisenburger DD, Anderson JR, et al: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 13:140-149, 2002
14. Zettl A, Rudiger T, Konrad MA, et al: Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 164:1837-1848, 2004
15. Martinez-Delgado B, Melendez B, Cuadros M, et al: Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 10:4971-4982, 2004
16. Ballester B, Ramuz O, Gisselbrecht C, et al: Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 25:1560-1570, 2006
17. Pinkus GS, O'Hara CJ, Said JW: Peripheral/post-thymic T-cell lymphomas: A spectrum of disease - clinical, pathologic, and immunologic features of 78 cases. Cancer 65:971-998, 1990
18. Hastrup N, Ralfkiaer E, Pallesen G: Aberrant phenotypes in peripheral T cell lymphomas. J Clin Pathol 42:398-402, 1989
19. Bubendorf L, Nocito A, Moch H, et al: Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72-79, 2001
20. Sabattini E, Bisgaard K, Ascani S, et al: The EnVision++ system: A new immunohistochemical method for diagnostics and research-Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 51:506-511, 1998
21. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
22. Baseggio L, Berger F, Morel D, et al: Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. Leukemia 20:296-303, 2006
23. Attygalle A, Al-Jehani R, Diss TC, et al: Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99:627-633, 2002
24. Attygalle AD, Diss TC, Munson P, et al: CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 28:54-61, 2004
25. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. JAMA 58:457-481, 1958
26. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
27. Cox DR: Regression models and life-tables. J R Stat Soc 34:187-220, 1982
28. Barry TS, Jaffe ES, Sorbara L, et al: Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 27:1513-1522, 2003
29. Gorczyca W, Tsang P, Liu Z, et al: CD30-positive T-cell lymphomas co-expressing CD15: An immunohistochemical analysis. Int J Oncol 22:319-324, 2003
30. Tiemann M, Schrader C, Klapper W, et al: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol 131:29-38, 2005
31. Sheval EV, Churakova JV, Dudnik OA, et al: Examination of the proliferative activity of tumor cells in human lymphoid neoplasms using a morphometric approach. Cancer 102:174-185, 2004
32. Mochen C, Giardini R, Costa A, et al: MIB-1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas. Cell Prolif 30:37-47, 1997
33. Caulet-Maugendre S, Patey M, Granier E, et al: Quantitative analysis of cellular proliferative activity in 35 T-cell non-Hodgkin's lymphomas: Use of proliferating cell nuclear antigen and Ki-67 (MIB-1) antibodies and nucleolar organizer regions. Anal Quant Cytol Histol 18:337-344, 1996
34. Montalban C, Obeso G, Gallego A, et al: Peripheral T-cell lymphoma: A clinicopathological study of 41 cases and evaluation of the prognostic significance of the updated Kiel classification. Histopathology 22:303-310, 1993
35. Miller TP, Grogan TM, Dahlberg S, et al: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 83:1460-1466, 1994
36. Rosenwald A, Staudt LM: Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 44:S41-S47, 2003 (suppl 3)
37. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74, 2002
38. Geissinger E, Odenwald T, Seung-Souk L, et al: Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8+ cytotoxic cells. Virchows Arch 445:334-343, 2004
39. Au WY, Ma SY, Chim CS, et al: Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: A single center experience of 10 years. Ann Oncol 16:206-214, 2005
40. Pileri S, Falini B, Sabattini E, et al: Immunohistochemistry of malignant lymphomas: Advantages and limitations of the new monoclonal antibodies working in paraffin sections. Haematologica 76:226-234, 1991
41. Ascani S, Zinzani PL, Gherlinzoni F, et al: Peripheral T-cell lymphomas: Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol 8:583-592, 1997
42. Weiss LM, Strickler JG, Dorfman DM, et al: Clonal T cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Am J Pathol 122:392-397, 1986
43. Tobinai K, Minato K, Ohtsu T, et al: Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. Blood 72:1000-1006, 1988
44. Feller AC, Griesser H, Schilling CV, et al: Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol 133:549-556, 1988
45. Ree HJ, Kadin ME, Kikuchi M, et al: Angioimmunoblastic lymphoma (AILD-type T-cell lymphoma) with hyperplastic germinal centers. Am J Surg Pathol 22:643-655, 1998
46. Nakamura S, Suchi T: A clinicopathologic study of node-based, low-grade, peripheral T-cell lymphoma: Angioimmunoblastic lymphoma, T-zone lymphoma, and lymphoepithelioid lymphoma. Cancer 67:2566-2578, 1991
47. Takagi N, Nakamura S, Ueda R, et al: A phenotypic and genotypic study of three node-based, low-grade peripheral T-cell lymphomas: Angioimmunoblastic lymphoma, T-zone lymphoma, and lymphoepithelioid lymphoma. Cancer 69:2571-2582, 1992
48. Ohshima K, Kikuchi M, Hashimoto M, et al: Genetic changes in atypical hyperplasia and lymphoma with angioimmunoblastic lymphadenopathy and dysproteinaemia in the same patients. Virchows Arch 425:25-32, 1994
49. Richel DJ, Lepoutre JM, Kapsenberg JG, et al: Epstein-Barr virus in a CD8-positive T cell lymphoma. Am J Pathol 136:1093-1099, 1990
50. Kaneko Y, Maseki N, Sakurai M, et al: Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive "angioimmunoblastic lymphadenopathy with dysproteinemia-type" features. Blood 72:413-421, 1988
51. Knecht H, Odermatt BF, Maurer R, et al: Diagnostic and prognostic value of monoclonal antibodies in immunophenotyping of angioimmunoblastic lymphadenopathy/lymphogranulomatosis X. Br J Haematol 67:19-24, 1987
52. Chott A, Augustin I, Wrba F, et al: Peripheral T-cell lymphomas: A clinicopathologic study of 75 cases. Hum Pathol 21:1117-1125, 1990
53. Boulland ML, Kanavaros P, Wechsler J, et al: Cytotoxic protein expression in natural killer cell lymphomas and in peripheral T cell lymphomas. J Pathol 183:432-439, 1997
54. Doi S, Nasu K, Arita Y, et al: Immunohistochemical analysis of peripheral T-cell lymphoma in Japanese patients. Am J Clin Pathol 91:152-158, 1989
55. Namikawa R, Suchi T, Ueda R, et al: Phenotyping of proliferating lymphocytes in angioimmunoblastic lymphadenopathy and related lesions by the double immunoenzymatic staining technique. Am J Pathol 127:279-287, 1987
56. Ohsaka A, Saito K, Sakai T, et al: Clinicopathologic and therapeutic aspects of angioimmunoblastic lymphadenopathy-related lesions. Cancer 69:1259-1267, 1992
57. Lee SS, Rudiger T, Odenwald T, et al: Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer 103:12-20, 2003
58. Yamamoto Y, Kitajima H, Sakihana H, et al: CD3+CD4-CD8-TCR-alphabeta+ T-cell lymphoma with clinical features of primary effusion lymphoma: An autopsy case. Int J Hematol 74:442-446, 2001
59. Barth TF, Leithauser F, Dohner H, et al: Primary gastric apoptosis-rich T-cell lymphoma coexpressing CD4, CD8, and cytotoxic molecules. Virchows Arch 436:357-364, 2000
60. Bekkenk MW, Vermeer MH, Jansen PM, et al: Peripheral T-cell lymphomas unspecified presenting in the skin: Analysis of prognostic factors in a group of 82 patients. Blood 102:2213-2219, 2003
61. Lanier LL, Le AM, Civin CI, et al: The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136:4480-4486, 1986
62. Monfardini S, Sorio R, Cavalli F, et al: Pentostatin (2′- deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: Phase II study of the EORTC Early Clinical Trials Group. Oncology 53:163-168, 1996
63. Knowles DM: Immunohistochemical markers useful in the diagnosis and classification of hematopoietic neoplasms, in Knowles DM (ed): Neoplastic Hematopathology (ed 2). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 93-226
64. Blakolmer K, Vesely M, Kummer JA, et al: Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas. Mod Pathol 13:766-772, 2000
65. Yao X, Teruya-Feldstein J, Raffeld M, et al: Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: A diagnostic pitfall. Mod Pathol 14:105-110, 2001
66. Quintanilla-Martinez L, Preffer F, Rubin D, et al: CD20+ T-cell lymphoma: Neoplastic transformation of a normal T-cell subset. Am J Clin Pathol 102:483-489, 1994
67. Cheng AL, Su IJ, Chen YC, et al: Characteristic clinicopathologic features of Epstein-Barr virus-associated peripheral T-cell lymphoma. Cancer 72:909-916, 1993
68. Kluin PM, Feller A, Gaulard P, et al: Peripheral T/NK-cell lymphoma: A report of the IXth Workshop of the European Association for Haematopathology. Histopathology 38:250-270, 2001
69. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
70. Sonnen R, Schmidt WP, Muller-Hermelink HK, et al: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 129:366-372, 2005
71. Savage KJ, Chhanabhai M, Gascoyne RD, et al: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15:1467-1475, 2004
72. Arrowsmith ER, Macon WR, Kinney MC, et al: Peripheral T-cell lymphomas: Clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma 44:241-249, 2003